Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2
diabetes.
Authors
Kim B, Backus C, Oh S, Hayes JM, Feldman EL
Submitted By
Eva Feldman on 3/24/2010
Status
Published
Journal
Endocrinology
Year
2009
Date Published
12/1/2009
Volume : Pages
150(12) : 5294 - 5301
PubMed Reference
19819959
Abstract
As the population of the United States ages, the incidence of age-related
neurodegenerative and systemic diseases including Alzheimer's disease (AD) and
diabetes is increasing rapidly. Multiple studies report that patients with
diabetes have a 50-75% increased risk of developing AD compared with age- and
gender-matched patients without diabetes. Abnormally phosphorylated tau is a
major building block of neurofibrillary tangles, a classic neuropathological
characteristic of AD. In addition, proteolytic tau cleavage promotes AD
progression due to cleaved tau serving as a nucleation center for the
pathological assembly of tau filaments. The current study examines tau
modification in type 1 (streptozotocin-injected) and type 2 (db/db) mouse models
of diabetes. Tau phosphorylation is increased in the cortex and hippocampus of
db/db mice compared with db+ control mouse brain. Interestingly, there is an
age-dependent increase in tau cleavage that is not observed in age-matched
control db+ animals. Streptozotocin injection also increased tau
phosphorylation; however, the increase was less significant compared with the
type 2 mouse model, and more importantly, no tau cleavage was detected. Our
results suggest tau modification caused by insulin dysfunction and hyperglycemia
may contribute to the increased incidence of AD in diabetes. We hypothesize that
type 1 and type 2 diabetes may contribute to AD through different mechanisms; in
type 2 diabetes, hyperglycemia-mediated tau cleavage may be the key feature,
whereas insulin deficiency may be the major contributing factor in type 1
diabetes.
Investigators with authorship
Name
Institution
Eva Feldman
University of Michigan
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Genes
Symbol
Description
Csnk1e
casein kinase 1, epsilon
Mapt
microtubule-associated protein tau
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!